Viatris and Ubie Launch Disease Awareness Project to Support Early Detection and Proper Consultation for Generalized Anxiety Disorder (GAD)

Viatris Japan and Ubie have launched a disease awareness project for GAD, utilizing AI to help potential patients recognize symptoms and seek appropriate medical care.
techNQ 54/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: May 28, 2026 at 14:01
  • 🔍 Collected: June 1, 2026 at 01:52 (83h 50m after Published)
  • 🤖 AI Analyzed: June 1, 2026 at 22:55 (21h 3m after Collected)
Viatris Inc., a global healthcare company, and Ubie, a medical AI startup, have launched a disease awareness project aimed at increasing public understanding of Generalized Anxiety Disorder (GAD) and supporting appropriate medical consultation for potential patients. GAD is characterized by chronic anxiety and worry, but patients often mistake these symptoms for personality traits, making it difficult to recognize as a medical condition. By combining Viatris's expertise in the psychiatric field with Ubie's AI platform, which serves over 13 million monthly users, the project aims to create new touchpoints for patients who previously lacked access to proper medical information. Both companies are committed to improving patients' quality of life and promoting public health by facilitating early diagnosis. GAD involves excessive, uncontrollable worry about daily life events and can manifest as physical symptoms. While the lifetime prevalence in Japan is reported at 2.6%, many patients remain undiagnosed. Through the 'Ubie' AI service, users can input symptoms to receive information on GAD and find nearby medical institutions, bridging the gap to professional care.

FAQ

What is the prevalence of GAD in Japan?

The lifetime prevalence is reported at 2.6%, while the prevalence of suspected GAD (GAD-7 score of 10+) is 7.6%.